Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-300 + Carboplatin/Pemetrexed in Never Smokers with Relapsed Advanced Lung Adenocarcinoma
NCT05456256Phase 2Recruiting
- Sponsor
- Lantern Pharma
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of dimesna in non-small cell lung cancer (NSCLC), sponsored by Lantern Pharma. Started Mar 2023; status: recruiting.
02
Drugs
dimesna
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05456256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456256.